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Abstract (298 words)  
Background 
A subset of patients with severe COVID-19 infection develop a hyperinflammatory syndrome 
(COV-HI), which may contribute to morbidity and mortality. This study explores the phenotype of 
COV-HI, and associations with escalation of respiratory support and survival.  
Methods 
In this retrospective, cohort study 269 consecutive adult inpatients were enrolled at University 
College London Hospitals and Newcastle upon Tyne Hospitals in the UK, between 1st and 31st 
March 2020, during the first wave of COVID-19 community-acquired infection. Demographic 
data, laboratory tests and clinical status were recorded from the day of admission until death or 
discharge with minimum follow-up of 28 days. Initial and repeated measures of 
hyperinflammation were evaluated in relation to next day risk of maximal level of respiratory 
support and death using a multilevel logistic regression model. 
Findings 
Clear differences were observed between the CRP (C-reactive protein) trajectories of patients 
with severe disease (defined by death or requiring ventilatory support) compared to those with a 
milder disease course. An operational definition of COV-HI (CRP >150mg/L or CRP doubling in 
24 hours from >50mg/L or ferritin >1500µg/L) was associated with poor outcome, as defined as 
the need for respiratory support or death. Of the whole cohort, 90 (33%) of patents met the 
COV-HI criteria at admission.  Despite being younger, and having fewer comorbidities, 40% of 
these patients died compared with 26% of the non-COV-HI patients.  In patients who were 
eligible for full respiratory support, 37% met the definition for COV-HI at presentation, and 75% 
met COV-HI criteria by the day of intervention.   
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Interpretation 
Associations between elevated inflammatory markers, escalation of respiratory support, and 
survival in people with COVID-19 infection are consistent with the existence of a high-risk (COV-
HI) inflammatory phenotype. COV-HI was often manifest on admission, followed a distinct 
trajectory, and may be useful to stratify patient groups in trial design.   
  
Funding 
This study did not receive any specific funding. NIHR UCLH Biomedical Research Centre and 
NIHR Newcastle Biomedical Research Centre contributed to infrastructure support at the 
respective centres.  
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Research in context (279 words) 
Evidence before this study 
We searched PubMed on 23rd May 2020 for studies published in English using search terms 
(“novel coronavirus” OR “2019 novel coronavirus” OR “2019-nCoV" OR "COVID-19") AND 
("hyperinflammation" OR "cytokine storm" OR "cytokine release” OR “HLH"). Four papers 
described differences in CRP and other inflammatory laboratory parameters in relation to 
outcome, one including longitudinal monitoring. A more recent study compared longitudinal 
changes in ferritin, D-dimer, and other tests between patients who survived or died, while a 
prospective cohort study of critically ill patients found an independent association between 
biomarkers of inflammation and in-hospital mortality. Numerous commentaries and review 
articles discussed hyperinflammatory syndromes in COVID-19 and the therapeutic potential of 
immunomodulation such as interleukin-6 blockade. Reservations have been expressed 
concerning appropriate selection criteria for intervention and potential risks of compromising 
anti-viral immunity and risk of secondary bacterial infection. 
Added value of this study 
A hyperinflammatory phenotype (COV-HI) defined by measurement of readily available routine 
clinical parameters was observed among a proportion of people admitted with COVID-19 
infection. In the total cohort, meeting the COV-HI criteria on admission was associated with a 
higher mortality (40% versus 26%). Amongst patients eligible for full escalation of treatment, 
37% fulfilled COV-HI criteria at admission, and 50% of these patients required escalation in 
respiratory support by 3 days.  In total, 75% of eligible patients met the criteria by the day they 
needed respiratory support.   
Implications of all the available evidence 
COV-HI is associated with adverse outcomes. A more detailed definition is achievable and 
desirable through further research and validation to develop a prediction model. This will 
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facilitate targeted trials of intervention with immunomodulation and identify patients likely to 





COVID-19, caused by infection with SARS-CoV-2, is associated with severe respiratory 
compromise and mortality of up to 21% in hospitalized patients1. Outcome is especially poor in 
patients requiring advanced respiratory support 2,3 with recent UK data reporting a mortality rate 
of 54.4% in this group (https://www.icnarc.org/Our-Audit/Audits/Cmp/Reports). Clinical 
deterioration often occurs 7-10 days after the onset of symptoms, in association with declining 
viral titres4.  This suggests that pathology is driven by inflammation rather than direct viral injury 
and inflammatory markers are often significantly elevated in patients with severe COVID-19 
infection3,5,6. Uncontrolled, self-perpetuating and tissue-damaging inflammatory activity 
(hyperinflammation) has also been described in the pathogenesis of previous coronavirus 
infections7. 
The term cytokine storm syndrome encompasses a number of overlapping, hyperinflammatory 
clinical syndromes. These include hemophagocytic lymphohistiocytosis (HLH), the macrophage 
activation-like syndrome (MALS) of sepsis, macrophage activation syndrome (MAS) and 
cytokine release syndrome8,9. The reported sensitivity of these syndromes to cytokine-directed 
therapy has fuelled intense speculation10-12 that outcome in a proportion of people with severe 
COVID-19 may also be ameliorated by immunomodulation of a hyperinflammatory response13-
16.  
Many trials using immunomodulatory/immunosuppressive drugs in COVID infection are now 
underway. Immunosuppression during infection incurs risk and the risk/benefit balance should 
be carefully accounted for in trial design. Previous experience from trials in sepsis for example 
demonstrate that lack of stratification may obscure positive results17. Therefore, improved 
understanding of hyperinflammation in COVID-19 is needed to inform trial design and ensure 
robust clinical research18,19. 
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Diagnostic criteria for hyperinflammation are incompletely defined, especially in the context of 
COVID-19.  Early studies of patients with COVID established independent associations between 
biomarkers of inflammation (such as C-reactive protein (CRP), IL-6 and ferritin) and severe 
disease (requiring respiratory support or resulting in death)2,3,5,20. Subsequent prospective 
studies have confirmed this association in large cohorts of people admitted to hospital with 
COVID infection21,22 and proposed that high levels of inflammatory biomarkers (CRP>200 and 
D-Dimer> 2500) are more strongly associated with critical illness than age or comorbidity21. This 
evidence forms the basis for initial predictive models and decision aids for those at risk of poor 
outcome23.  
 
We agreed an operational definition of COVID-19 associated hyperinflammation (hereafter 
referred to as COV-HI) based on emerging evidence from the literature, 3,12,15,18,24  from clinical 
observation and from extensive discussion with members of a UK group of specialists in 
hyperinflammation (the HLH Across Specialty Collaboration, HASC).  Given that viruses are well 
known to cause HLH in a subgroup of patients, we also proposed to investigate the usefulness 
of the HLH diagnostic tool, the H-score, in the context of SARS-CoV-2 infection25.  
 
In this study, we aimed to test and assess hyperinflammation in COVID-19 by evaluating 
longitudinal associations between hyperinflammatory biomarkers, disease severity and survival.  
We applied proposed COV-HI criteria and the H-Score to our cohort.  We sought to determine 
whether it was possible to identify patients with hyperinflammation on admission, or who 
developed hyperinflammation during their admission, and how hyperinflammation related to any 
deterioration in clinical status. We did not seek to develop an outcome prediction model based 
on hyperinflammation from this initial cohort as sample size calculations indicated 500-1000 






Approval: The study COVID-19 hyperinflammation syndrome (COV-HI): protocol for a rapidly 
executed cohort study (REC ref 20/YH/0138 and IRAS ID 282626) received ethical approval 
from Yorkshire & The Humber - Leeds West Research Ethics Committee and approval by the 
Health Research Authority and Health and Care Research Wales (HCRW) on 15th April 2020. 
The study was registered at the Clinical Trials Gateway (NCT04385069), NIHR portfolio 
(ID45542) and HRA website (https://www.hra.nhs.uk/covid-19-research/approved-covid-19-
research/). 
 
Study population, eligibility and follow up: Consecutive patients ≥18 years of age with a 
positive PCR for SARS-CoV-2 admitted to University College London Hospitals (UCLH) or 
Newcastle Upon Tyne Hospitals (NUTH) for treatment of community-acquired COVID-19-related 
illness as defined by the WHO (WHO Department of Communications 2020) from 1st March to 
31st March 2020 were considered for inclusion.  The only exclusion criteria was the use of 
home NIV (non-invasive ventilation). Patients were followed until death, or hospital discharge or 
up to 28 days from admission. 
 
Laboratory tests: SARS-CoV-2 was detected in nasal and throat swabs using RT-PCR26.  
Routine blood tests that we recorded were those carried out in the usual clinical care of each 
patient and, where available, included full blood count, coagulation profile, renal and liver 
function, C-reactive protein (CRP), ferritin, D-dimer, lactate dehydrogenase, and troponin. All 
available patient data were collected daily from both sites until escalation of respiratory support 




Clinical data and definitions:  
Co-morbidity was recorded using the Charlson Comorbidity Index27 from the patient record and 
categorised as none, single or multiple/severe comorbidities. Patients were designated as ‘not 
for escalation’ if any of the following statements were found in medical records within 24 hours 
of admission: a community DNA-CPR (do not attempt cardio-pulmonary resuscitation) order or a 
hospital treatment escalation plan of DNA-CPR; for ward-based care only; not for NIV (non-
invasive ventilation); not for mechanical ventilation.  In most cases these statements were highly 
overlapping, with the exception of a small number of patients who received NIV in a ward-based 
setting or who received escalated support but had advance directives not for CPR (both 
included in the subgroup “for escalation”).  A 24-hour limit was chosen to identify those initially 
too frail or sick for escalation, and to avoid including decisions made later in the disease course 
after initial support and interventions had failed.  
Respiratory support was categorised as: ‘supplemental oxygen’ when delivered by nasal 
cannulae or face mask; NIV when non-invasive pressure support was supplied by face mask; 
and ‘intubation’ when ventilation was delivered by endo-tracheal or tracheostomy tube. 
Escalation of respiratory support was defined as a transition from supplemental oxygen to either 
NIV or intubation.   
We derived an operational definition of hyperinflammation from the literature on sHLH in sepsis, 
the H-score and the emerging reports that indicators of hyperinflammation including CRP and 
ferritin were significantly associated with poor outcome in COVID-193,12,15,18,24.  
‘Hyperinflammation’ as a categorical variable was defined as any of the following: CRP 
>150mg/L; CRP doubling in 24 hours from >50mg/L; ferritin >1500µg/L. These cut-offs were 
agreed from the literature review3,12,15,18,24 , clinical observation and from extensive discussion 
with members of a UK group of specialists in hyperinflammation (the HLH Across Specialty 
Collaboration, HASC).  including a subset of the authors of this work (RT, JJM, MC, PM, BG, 
MN, MB, MS).    
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From the clinically available information collected longitudinally during the study we calculated 
the H-score as defined according to Fardet et al.25 but modified this to omit assessment of 
organomegaly and bone marrow cytology (difficult to ascertain in patients with COVID-19). Thus 
the new possible total score was 264, with the median score suggestive of sHLH used as cut-off 
of 132; following the model from Kyriazopoulou et al.28 
 
Data management: Demographic, clinical, laboratory, treatment, and outcome data were 
extracted from electronic medical records using a bespoke web-based REDCap database29 
developed by TD, BCL and MC at the Newcastle Joint Research Office.  The data dictionary is 
available on request. Data were entered by members of the research or clinical care teams 
using a protocol jointly developed by the two centres.  Anonymised data were downloaded from 
REDCap for statistical analysis by CC and JW.  Outliers (implausible values) for variables and 
dates were identified and clarified with the data entry teams.   
 
Statistical methods: Continuous and categorical variables are reported as median (IQR) and n 
(%), respectively. Escalation-free survival was estimated using Kaplan Meier curves with death 
or escalation to NIV or intubation as events and surviving patients censored at day 28.  Scatter 
plots of daily results were plotted against time for longitudinal analysis. Missing data in baseline 
categorical values were included as a separate category. Missing daily values were imputed 
only for the repeated measures multivariate model below, by carrying forward results from the 
previous day. This reflects the reality of the information that would have been available to a 
clinician at any given time point. If more than one result was recorded on a given day, the most 
deviated result was selected at data entry. The moving average for each variable was overlaid 
using a LOESS curve showing 95% confidence intervals for the estimated daily mean. 
Depending on the analysis, time was centred on the date of first symptoms or the date of 
escalation, as described in figure legends. The other parameters in the LOESS models used 
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default settings with a polynomial of degree 2, interpolation on a cell size of 0.2, and a Gaussian 
(fitted least squares) kernel.  
 
To interrogate factors associated with escalation of respiratory support or in-hospital mortality, 
we fitted a Cox proportional hazards model with time varying covariates for the repeated 
laboratory results with time measured from day of symptom onset.  A forward step-wise model 
building approach was used from an initial model including three a priori variables:  
hyperinflammation as defined above; age and sex.  Additional variables: lymphocyte count, 
comorbidity (Charlson index); steroids or immunosuppressants on admission; were selected for 
inclusion if they improved model fit as measured by a reduction in the Akaike Information 
Criterion.  Where appropriate we log transformed variables to fit in the model. Age on hospital 
admission was included as a linear variable, but was also tested for a departure from this linear 
trend.  
Sample size: 
We did not plan any predictive modelling in this study as sample size calculations indicated the 
need for between 500 and 1000 patients.  Instead we pragmatically decided to analyse the first 
tranche of data when it was complete and 28 days of follow up had occurred after the last 





Patient demographics and baseline characteristics of COVID-19 patients stratified by 
escalation of care 
Data were collected on 269 consecutive patients ≥18 years of age who presented to UCLH and 
NUTH between 1st and 31st March 2020 with a positive swab for SARS-CoV-2 PCR and who 
were followed up until death or discharge for a maximum of 28 days. Baseline demographics of 
the cohort are summarised in Appendix page 1. The median age was 71 years, 62% were 
male and 26% were of Black, Asian or Minority Ethnic backgrounds. Except for ethnicity, no 
significant differences were seen in baseline characteristics between patients recruited in the 
two hospitals. These included proportions deemed not fit for escalation, rate of escalation to NIV 
or intubation, and overall mortality. Date of symptom onset preceding admission was recorded 
in almost all records; in 15 (6%) cases this was missing and the date of admission was used as 
the date of onset instead.   
 
Treatment escalation plans indicating that patients were not for escalation of care above 
supplemental oxygen were recorded in 91 patients (33.8%).  Of these, 50 (54.9%) patients 
survived until the end of the 28-day follow up. (Appendix page 2).  On average, these patients 
were older and had higher Charlson scores than those eligible for escalation of respiratory 
support (Appendix page 3).  Of those eligible for escalation, 137 (77.0%) survived; however 
only 56.7% of patients needing non-invasive or invasive ventilation remained alive at the end of 
follow up compared to 97.7% who did not require escalation of care (Appendix page 2).   
 
Baseline laboratory results of the cohort are summarized in Appendix page 4. In patients who 
were eligible for escalation and subsequently died, lymphocyte count was lower and CRP 
higher, compared with those who were escalated and survived.  Missing data were low for 
routine blood tests.  Of inflammatory markers, only CRP was recorded reliably (90% of patients) 
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whereas ferritin, D-dimer, LDH and other measures were reported on ≤50% of patients at 
admission (Appendix page 4).   
 
Patients eligible for escalation who did not survive had a high CRP trajectory 
 
To synchronise the course of COVID-19 in patients presenting at different stages in their illness 
we plotted mean daily blood test values versus elapsed time since the onset of symptoms using 
the onset of symptoms as a datum (Figure 1). As expected, a higher level of inspired oxygen 
(FiO2) was required by patients who required NIV or intubation. Divergent CRP trajectories were 
apparent between patients not for escalation or receiving oxygen only, those escalated to NIV, 
and those who required mechanical ventilation. People who required mechanical ventilation 
showed a higher mean CRP, peaking at 247mg/L (day 13), compared to a peak of 153mg/L 
(day 10) in the group requiring NIV only. The bar chart of daily status and Appendix page 6 
show that the early trends in CRP were mainly related to the mean values of patients, with the 
possibility of survivor bias from loss to discharge and death mainly arising at the time of the 
peak values. 
 
Levels of creatinine, neutrophils and lymphocytes also varied between one or more subgroups, 
with lower lymphocyte counts being seen in the groups with worse clinical outcomes, and 
highest neutrophil counts seen late in the disease process in patients requiring mechanical 
ventilation.   
 
Among the 89 patients whose care was escalated, the daily means of sequential tests were 
compared in survivors and non-survivors indexing their clinical course at the point of escalation 
(Figure 2).  Although this showed similar trajectories of CRP, neutrophils and lymphocytes 
before the intervention, a delayed, higher peak CRP, and a greater degree of neutrophilia and 
more marked lymphopenia were observed in patients who eventually died. The most noticeable 
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changes occurred in the first 5 days before the possibility of bias increased from loss to death 
and discharge (Appendix page 6). 
 
Insufficient data were collected to perform an H-score in the majority of patients in this cohort 
reflecting a lack an awareness of the score and clinical practice in a pandemic. Of the 47 
patients who had sufficient data to calculate an H-score, the median was well below the cut-off 
indicating sHLH in the proposed modified score. (Appendix page 7).   
 
Hyperinflammation was associated with inferior escalation-free survival – admission data 
 
Admission definition for COV-HI was CRP >150mg/L or ferritin >1500µg/L, as doubling of CRP 
was not possible with single measures. Of the whole cohort, 90 (33%) of patents met the COV-
HI criteria at admission. Despite being younger (66 versus 71 years), and having fewer 
comorbidities (Charslon Score 1 versus 2), 40% of these patients died compared with 26% of 
the non-COV-HI patients (Appendix page 8). The majority of people meeting the criteria for 
COV-HI on their admission to hospital did so by virtue of having a CRP>150mg/ml. However 
16/90 (18%) met the definition on the basis of ferritin 1500µg/L or greater (Appendix page 9). 
 
Of the 91 patients in the whole cohort who were not eligible for escalation, 25 met the COV-HI 
(27%) criteria on the day of admission and of these 17 died by 28 days (68%) (Table 1).   
Looking at patients with no ceiling of care, escalation-free survival was worse among those with 
hyperinflammation at admission after adjusting for age, sex and Charlson co-morbidity 
(likelihood ratio test, p< 0.0001) (Figure 3A). Admission CRP and ferritin (where recorded) were 
higher in patients eligible for escalation who did not survive, compared with those who remained 
alive (Appendix page 4).   
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Hyperinflammation was associated with inferior escalation-free survival – longitudinal 
data 
 
On the day of admission, 65/178 (37%) patients eligible for escalation met the criteria for COV-
HI, of whom 19 subsequently died (26%) (Table 1).  50% of patients meeting criteria for COV-HI 
at admission required escalation of respiratory support by 3 days (95% CI 1-4) (Figure 3A). In 
patients without hyperinflammation (i.e. not meeting COV-HI criteria throughout their 
admission), (95/178), or those with missing data (18/178), the endpoint of escalation to 
respiratory support was not reached by 28 days (therefore it is not possible to calculate a 
median escalation-free survival). Furthermore, the association between any increased CRP or 
ferritin measurement, and the need for next day escalation remained significant (Hazard Ratio 
2.2 (1.6 - 2.9) on a daily basis after adjustment for age, sex, and co-morbidity (Table 2 and 
Appendix page 10 for additional adjustments). In the fitted time varying Cox model there was 
no clear systematic pattern in the residuals for the key predictors, and a fitted line was 
approximately horizontal, so given the number of data points the proportional hazard 
assumption was appropriate (Schoenfeld residual plots and log(-log) plots are shown in 
Appendix page 12).  Within this model there was no evidence to support a direct association of 
escalation with site (p = 0.95) and no evidence for an interaction by site of the association of 
COV-HI with escalation (p=0.8).  75% of patients who were eligible for escalation met the 





By longitudinal observation of a cohort of patients admitted with COVID-19 to two hospitals in 
the UK, this study supports the concept that a proportion of patients have a hyperinflammatory 
phenotype (COV-HI) and that meeting the criteria for this phenotype is associated with a poor 
clinical outcome. Striking differences were observed between the CRP trajectories of patients 
whose disease was severe, as defined by death or requiring ventilatory support, and those 
whose disease followed a milder course.  
 
In patients who were eligible for escalation of care, we found an independent association 
between patients meeting COV-HI criteria and their need for ventilatory support or death, once 
we had accounted for age, sex and comorbidity. Furthermore, by applying criteria for COV-HI to 
this patient cohort, we showed that 37% could be identified at presentation, and 75% of patients 
who went on to need ventilatory support met these criteria before the point for escalation was 
reached.  Our work builds on, and contributes to, the evidence enabling risk prediction models 
for people with COVID infection. 
 
In patients who had a ceiling of care determined at admission and were therefore not for 
escalation to respiratory support, meeting COV-HI criteria was associated with a mortality of 
68%. In those patients for whom respiratory support was an option mortality was 29%. The 
cause of the higher mortality in the former group cannot be extrapolated from our data, but may 
relate to confounders such as frailty/multi-morbidity, or suggest that respiratory support can 
improve outcome in patients with a hyperinflammatory response to COVID-19.  
 
The thresholds we used to define COV-HI (CRP >150mg/L or CRP doubling in 24 hours from 
>50mg/L or ferritin >1500µg/L) were in line with, or more stringent than, reported elsewhere 
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3,15,18,24.  The use of CRP and ferritin, both readily available and inexpensive, were routinely and 
reliably collected in the majority of patients; by contrast in this real-world study, some key data 
required for calculating an H-score were only available for a minority of patients. We therefore 
could not draw firm conclusions about the role of the H-score as so few patients had the 
required clinical data to complete the score. In the small minority where an H-Score could be 
calculated, the result did not suggest a high probability of sHLH.  
 
There is an emerging body of evidence that hyperinflammation in COVID infection is distinct 30 
from other recognised hyperinflammatory states, and this is part of a wider debate regarding the 
definition and aetiopathogenesis of cytokine storm syndromes. CRP appears to be an important 
marker of poor outcome in COVID-19 infection in particular and the majority of patients who met 
the COV-HI criteria in this study did so on the basis of the CRP criteria. The role that CRP plays 
in predicting outcome in COVID-19 is in contrast to studies in other conditions leading to 
pneumonia/ARDS in the literature where CRP is not found to be prognostically useful in 
predicting deterioration31,32.  
 
Elevated ferritin has been used in risk models for the hyperinflammatory subtype of sepsis, (so 
called macrophage activation like syndrome, or MALS), defined as a ferritin of >4420ng/ml28.  
Although we have shown median ferritin levels in this cohort of people with COVID-19 infection 
were significantly lower than those in MALS, an on-going study with a larger cohort will hope to 
address the question of whether there are subtypes of hyperinflammatory disease caused by 
SARS-CoV-2 infection defined by different biomarker thresholds.  Previous work in sepsis and 




The highly elevated CRP results in our study raise the question of superadded bacterial 
infection, but a recent review of the literature supports our clinical experience that very little 
bacterial (or fungal) infection was seen34.  We also demonstrated a late spike in CRP associated 
with raised neutrophils in the group in our study requiring ventilation which may represent 
ventilator associated pneumonia. This potential phenomenon would not affect the validity of our 
proposed COV-HI definition because in our methodology this was applied before escalation to 
respiratory support. 
 
In contrast to many recent studies, which rely on single data points, we have been able to 
estimate the association between longitudinal, repeated measurements of laboratory markers 
and clinical outcome. The main limitation of this dataset is that ‘last value carried forward’ was 
used in our modelling, which is a known source of potential bias. This was the only option 
available to us for the purposes of modelling risk of escalation (to be able to include the 
longitudinal repeated measurements) and partly reflects the real-world situation when a doctor 
is assessing a patient clinically. Of note, we had complete follow up until 28 days post-
admission including out of hospital deaths. This is a longer and more complete follow up than 
many recent reports35.   
 
There is an emerging literature which supports our findings that inflammatory markers are 
strongly associated with critical illness and mortality21 in people with COVID-19 infection and 
suggests that clinicians should measure such markers routinely. Such emerging evidence also 
mandates further study to inform the understanding of inflammation and hyperinflammation in 
COVID-19. While some prognostic models for COVID-19 have been published, either in preprint 
form or fully, all those considered in a recent systematic review and meta-analysis were found to 
be at high risk of bias35. We have not attempted to create a prognostic score using our data; 
instead we have simply estimated the association between hyperinflammation and outcome. 
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This study was not appropriately powered to examine thresholds via a derivation and validation 
approach, or to define a risk prediction model. However, using simple biomarkers associated 
with hyperinflammation (CRP and ferritin), we have identified a potential clinical phenotype 
(COV-HI) associated with poor outcome in severe COVID-19 infection.  
 
In conclusion, we have shown there is an association between readily available and commonly 
tested inflammatory biomarkers, the need for escalation of respiratory support, and risk of death 
in people with COVID-19 infection. This supports the concept that a high-risk inflammatory 
phenotype, COV-HI, exists, and may be associated with higher mortality. The COV-HI criteria 
need to be validated in a larger cohort but have the potential to be developed as an easy 
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Figure 1: Longitudinal monitoring and escalation of respiratory support. Laboratory results 
were plotted against time. LOESS curves are shown fitted from mean daily worst values from 
day of symptom onset for all patients plotted by highest required respiratory support during 
admission (fitted loess curve showing mean and 95% CI-shaded area, missing data imputed 
from last value carried forward, the other parameters in the models used default settings with a 
span = 50%, polynomial of degree 2, interpolation on a cell size of 0.2, and a Gaussian (fitted 
least squares) kernel). These plots were stratified as follows: Among all patients, longitudinal 
mean values were stratified by the highest level of respiratory support during the admission. 
Those with a clinical decision to not attempt cardiopulmonary resuscitation (DNACPR) nor to 
escalate support beyond ward-based care were included as a separate category. NIV, non-









Figure 2:  LOESS curves fitted from worst daily mean values stratified by overall survival 
centred on day of increased respiratory support, only patients eligible for escalation who 
received increased respiratory support (fitted loess curve with mean and 95% CI-shaded area, 
the other parameters in the models used default settings with a span = 50%, polynomial of 
degree 2, interpolation on a cell size of 0.2, and a Gaussian (fitted least squares) missing values 
imputed by last value carried forward). Daily numbers in each category are shown and 



















Figure 3: Hyperinflammation was associated with inferior escalation-free survival  
(A) The combined outcome of death or need for ventilation support was defined in patients 
eligible for respiratory support (patients censored at 30 days on end of study follow up). Kaplan 
Meier curves are plotted from the first day of data collection for each patient. These were 
stratified by whether hyperinflammation criteria were met (CRP >150mg/L or ferritin >1500ug/L) 
on the day of cohort entry. Patients without CRP or biochemistry recorded on admission day 
were included as a missing category. The difference in ventilation free survival between those 
who met or did not meet hyperinflammation criteria was tested with a log rank test. Predicted 
median survival is indicated by the dashed line for the hyperinflammatory group only. 
(B) Daily percentage of patients meeting the criteria for hyperinflammation (CRP >150mg/L or 
CRP doubling in 24 hours from >50mg/L or ferritin >1500µg/L) from the day of their symptom 
onset until the day that they needed ventilatory support – 74% of the total population for whom 
escalation could be considered had met the criteria by the day that they do need support. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
